Buscar
-
The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation
(Cancers. vol. 11, n° 12, 2019-12)Article de revueLibre acceso -
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.
(Genes, Chromosomes & Cancer. vol. 62, n° 3, pp. 139-151, 2023-03-01)Article de revue -
Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells
(Blood. vol. 134, n° 26, pp. 2383–2387, 2019-12)Article de revueAcceso reservado -
STAT5-and hypoxia-dependent upregulation of AXL
(Haematologica. vol. 104, n° 10, pp. 2017–2027, 2019-10)Article de revueLibre acceso -
JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens
(Leukemia & lymphoma. vol. 57, n° 8, pp. 1949–1951, 2016-08)Article de revue -
Clonal hematopoiesis are not associated with an increased systemic inflammation, ATHerosclerosis nor incidence of atherothrombosis: Results from the 3-city study (CHIP-3C)
(Atherosclerosis. vol. 355, pp. 29, 2022-08-01)Article de revueLibre acceso -
Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms.
(Journal of Thrombosis and Haemostasis, 2023-09-09)Article de revue -
Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutation
(Research and Practice in Thrombosis and Haemostasis. vol. Vol. 7, n° Issue 2, pp. 100060, 2023-02)Article de revueLibre acceso -
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
(American Journal of Hematology, 2024-02-25)Article de revueLibre acceso -
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs.
(Haematologica, 2024-02-08)Article de revueLibre acceso